Comprehensive registry of esophageal cancer in Japan, 2014
| Autor: | Ryu Ishihara, Takashi Uno, Koji Tanaka, Hiroaki Miyata, Kentaro Murakami, Takahiro Tsushima, Hiroshi Saeki, Masayuki Watanabe, Kei Muro, Masaki Ueno, Yasushi Toh, Soji Ozawa, Toshiyuki Yoshio, Arata Takahashi, Hisahiro Matsubara, Hodaka Numasaki, Tsuneo Oyama, Shiyori Usune, Koji Kono |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Esophageal Neoplasms medicine.medical_treatment Esophageal cancer Metastasis Special Article Japan Medicine Chemotherapy Humans Registries Survival analysis Cancer staging Radiotherapy business.industry General surgery Gastroenterology Chemoradiotherapy medicine.disease Radiation therapy Esophagectomy Endoscopic resection Carcinoma Squamous Cell Adenocarcinoma business |
| Zdroj: | Esophagus |
| ISSN: | 1612-9067 1612-9059 |
| Popis: | Background The registration committee for esophageal cancer in the Japan Esophageal Society (JES) has collected the patients' characteristics, treatment, and outcomes annually. Methods We analyzed the data of patients who had visited the participating hospitals in 2014. We collected the data with a web-based data collection system using the National Clinical Database. We used the Japanese Classification of Esophageal Cancer 10th edition by JES and the TNM classification 7th edition by the Union of International Cancer Control (UICC) for cancer staging. Results A total of 9026 cases were registered from 344 institutions in Japan. Squamous cell carcinoma and adenocarcinoma accounted for 87.9% and 7.1%, respectively. The 5-year survival rates of patients treated using endoscopic resection, concurrent chemoradiotherapy, radiotherapy alone, and esophagectomy were 87.1%, 33.7%, 25.3%, and 59.3%, respectively. Esophagectomy was performed in 5204 cases. Concerning the approach used for esophagectomy, 48.1% of the cases were treated thoracoscopically. The operative mortality (within 30 days after surgery) was 0.75%, and the hospital mortality was 2.0%. The survival curves showed an excellent discriminatory ability both in the clinical and pathologic stages by the JES system. The survival of pStage IV was better than IIIC in the UICC system, because pStage IV included the patients with supraclavicular lymph-node metastasis (M1 LYM). Conclusion We hope that this report contributes to improving all aspects of diagnosing and treating esophageal cancer in Japan. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink